PCV38 The IMPACT on Clinical an Economic VALUE of Patient Prioritization According to Risk: Evolocumab in Patients with Myocardial Infarction in Sweden

E Hagström,P Lindgren,G Villa,L Martinez,J Arellano,M Eriksson Svensson,G.C Fonarow

doi:10.1016/j.jval.2020.08.529

PCV38 The IMPACT on Clinical an Economic VALUE of Patient Prioritization According to Risk: Evolocumab in Patients with Myocardial Infarction in Sweden

E Hagström, P Lindgren + Show 5 more

Open Access

https://doi.org/10.1016/j.jval.2020.08.529

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2020
License type: publisher-specific-oa

Affiliation: Uppsala University, Swedish Institute for Health Economics, Karolinska Institutet, Amgen (Switzerland), Amgen (United States), University of California, Los Angeles

#Myocardial Infarction In Sweden #Infarction In Sweden + Show 4 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PCV38 The IMPACT on Clinical an Economic VALUE of Patient Prioritization According to Risk: Evolocumab in Patients with Myocardial Infarction in Sweden

Full Text